SIRPA and neoplasm: This highlights the importance of CD47 in early-stage lung cancer progression.87 Monoclonal antibodies that block the CD47-SIRPα interaction are being investigated as a promising cancer treatment.88,89 By blocking CD47, these antibodies can restore macrophage-mediated phagocytosis of tumor cells, thus enhancing the anti-tumor immune response.